Drug Profile
Research programme: induced pluripotent stem cell-derived therapeutics - Foundation for Biomedical Research and Innovation /RIKEN/Santen
Alternative Names: iPS therapeutics - Santen PharmaceuticalLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Foundation Fighting Blindness Clinical Research Institute; RIKEN; Santen Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Retinitis-pigmentosa in Japan (Parenteral)
- 06 Nov 2016 Santen Pharmaceutical, RIKEN, and the Foundation for Biomedical Research and Innovation agree to co-develop induced pluripotent stem cell-derived therapeutics in Japan for Retinitis pigmentosa and Age-related macular degeneration
- 06 Oct 2016 Early research in Retinitis pigmentosa and Age-related macular degeneration in Japan